About Surgery Partners, Inc. - Common Stock (SGRY)
Surgery Partners is a leading provider of surgical services, focused on delivering high-quality, cost-effective healthcare solutions. The company operates a network of ambulatory surgery centers and surgical hospitals, offering a diverse range of surgical procedures across various specialties. By collaborating with physicians and healthcare professionals, Surgery Partners aims to enhance patient experiences and outcomes while ensuring efficient operational processes. Their commitment to quality care, innovation, and patient-centered services positions them as a key player in the healthcare industry, addressing the growing demand for outpatient surgical services. Read More
Surgery Partners reported Q1 revenue of $776 million and earnings of 4 cents per share, reaffirming its 2025 guidance despite missing analyst expectations.
Healthcare company Surgery Partners (NASDAQ:SGRY) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.2% year on year to $776 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $3.38 billion at the midpoint. Its non-GAAP profit of $0.04 per share was $0.01 below analysts’ consensus estimates.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 12.7%. This performance was worse than the S&P 500’s 7.5% fall.
A number of stocks fell in the afternoon session after President Trump criticized the Federal Reserve's approach to interest rate cuts, warning that the pace was slow and could hinder economic growth. Trump's comments added pressure to an already sensitive market, raising concerns about political interference in monetary policy.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Encompass Health (NYSE:EHC) and its peers.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at outpatient & specialty care stocks, starting with Select Medical (NYSE:SEM).
Let’s dig into the relative performance of DaVita (NYSE:DVA) and its peers as we unravel the now-completed Q4 outpatient & specialty care earnings season.
What a brutal six months it’s been for Surgery Partners. The stock has dropped 29.9% and now trades at $21.10, rattling many shareholders. This might have investors contemplating their next move.
Let’s dig into the relative performance of agilon health (NYSE:AGL) and its peers as we unravel the now-completed Q4 outpatient & specialty care earnings season.
Healthcare company Surgery Partners (NASDAQ:SGRY) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 17.5% year on year to $864.4 million. The company expects the full year’s revenue to be around $3.38 billion, close to analysts’ estimates. Its non-GAAP profit of $0.44 per share was 16.7% above analysts’ consensus estimates.
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners experiencing significant growth due to strategic developments.
